Losartan
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Losartan: From Hypertension to Malignant Hypertensive Renal Disease
One-Sentence Summary
Losartan is a selective angiotensin II type 1 (AT1) receptor blocker (ARB), clinically proven for the treatment of hypertension and diabetic nephropathy. The TxGNN model predicts it may be effective for Malignant Hypertensive Renal Disease, with 0 clinical trials and 1 publication currently supporting this direction. The mechanistic rationale is strong—RAAS overactivation is a core driver of malignant hypertensive nephrosclerosis—but dedicated clinical evidence remains absent.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension, Diabetic Nephropathy |
| Predicted New Indication | Malignant Hypertensive Renal Disease |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, Losartan is a selective AT1 receptor antagonist that competitively blocks angiotensin II from binding to its primary receptor subtype. This prevents angiotensin II from triggering vasoconstriction, aldosterone secretion, sodium retention, and downstream pro-inflammatory signalling—including the NF-κB pathway. Its efficacy in essential hypertension and hypertensive nephropathy has been well-established in landmark clinical trials such as LIFE and RENAAL.
Malignant hypertensive renal disease (malignant hypertensive nephrosclerosis) is defined by severely uncontrolled blood pressure causing acute end-organ injury to the kidneys, characterised histologically by fibrinoid necrosis of arterioles and onion-skin intimal hyperplasia. The central pathological driver is RAAS overactivation—angiotensin II exerts intense afferent arteriolar vasoconstriction, promotes glomerular ischaemia, and amplifies NF-κB-mediated renal inflammation. This pathophysiology maps directly onto Losartan’s mechanism of action, making the TxGNN prediction mechanistically coherent.
Supportive animal evidence (PMID 30809002) demonstrates the pathogenic role of angiotensin II and the NF-κB system in a rat model of malignant hypertensive nephrosclerosis. While renin-angiotensin blockade is already recommended in chronic hypertensive nephrosclerosis, the specific application in the acute malignant phenotype—where the safety balance (risk of precipitous renal function decline) requires careful evaluation—has not been formalised through dedicated clinical trials, leaving a clear research gap that this prediction highlights.
Clinical Trial Evidence
Currently no related clinical trials registered for Losartan in malignant hypertensive renal disease.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30809002 | 2019 | Animal/Mechanistic | Hypertension Research | In a rat model where NF-κB inhibition during lactation induced adult-onset hypertension, uninephrectomy plus salt overload unmasked latent renal dysfunction and promoted malignant hypertensive nephrosclerosis; angiotensin II and the NF-κB pathway were identified as key pathogenic drivers, directly supporting the rationale for AT1 receptor blockade |
India Market Information
Losartan (DB00678) is not currently registered or marketed in India. No CDSCO authorization records are on file (0 total licenses). A formal marketing authorization application would be required before any clinical use.
Safety Considerations
Drug Interactions (253 total known interactions; selected clinically significant interactions shown):
Major interactions requiring close management or avoidance:
| Interacting Drug | Level | Clinical Concern |
|---|---|---|
| Potassium citrate | Major | Additive potassium retention; risk of life-threatening hyperkalemia |
| Potassium bicarbonate | Major | Additive potassium retention; risk of hyperkalemia |
Selected moderate interactions of practical importance:
| Interacting Drug | Level | Clinical Concern |
|---|---|---|
| Corticosteroids (Hydrocortisone, Dexamethasone, Betamethasone, Budesonide, Triamcinolone) | Moderate | Corticosteroids antagonise antihypertensive effect and promote sodium/water retention |
| SGLT2 Inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin) | Moderate | Additive blood pressure–lowering and volume-depleting effects; monitor for hypotension and acute kidney injury |
| Insulins (Insulin aspart, Insulin glargine, Insulin human isophane) | Moderate | ARBs may enhance insulin sensitivity; monitor blood glucose for hypoglycaemia |
| Acetylsalicylic acid | Moderate | NSAIDs/aspirin may blunt antihypertensive efficacy and increase risk of renal impairment |
| Morphine | Moderate | Additive hypotensive effect; monitor blood pressure |
| Aprepitant | Moderate | CYP3A4 interaction may alter Losartan exposure |
| Bupropion | Moderate | Monitor for blood pressure changes |
Please refer to the package insert for complete key warnings and contraindications, which were not available in this Evidence Pack.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic case for Losartan in malignant hypertensive renal disease is highly plausible—AT1 receptor blockade directly targets the RAAS overactivation underpinning the disease—but current evidence is limited to a single animal/mechanistic study (L4), with no registered clinical trials and no India marketing authorisation in place. Critical safety data from the package insert (key warnings, contraindications in the malignant hypertension setting) are also outstanding.
To proceed, the following is needed:
- Obtain Losartan package insert (CDSCO-approved or international reference label) to clarify contraindications and warnings specifically relevant to malignant hypertension (e.g., bilateral renal artery stenosis risk)
- Retrieve full DrugBank MOA and toxicity data for mechanistic documentation
- Conduct a systematic literature search for ARB use in malignant hypertensive nephrosclerosis to determine whether existing real-world or retrospective data support a Phase 2 hypothesis
- Evaluate whether Losartan’s active metabolite (EXP3174) offers any pharmacokinetic or pharmacodynamic advantage over other ARBs in this acute-severity setting
- If evidence is deemed sufficient, initiate regulatory pre-consultation with CDSCO regarding marketing authorisation pathway and potential indication expansion requirements
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.